• SENSEX
    NIFTY 50
Business

Delay in FTC approval for Aurobindo Pharma, Sandoz deal raises questions, says report

Updated : July 31, 2019 09:59 AM IST

Last year, Aurobindo had announced that it would acquire the commercial operations of Swiss drugmaker Novartis AGs’ generics unit in the US for $900 million.
the development comes a month after  Aurobindo received a warning letter from the US Food and Drug Administration (FDA) for one of its units in Srikakulam.
Delay in FTC approval for Aurobindo Pharma, Sandoz deal raises questions, says report

You May Also Like

Live TV
Advertisement